| Business Summary | | Albany
Molecular
Research,
Inc.
is
a
drug
discovery
and
development
company
focused
on
applications
for
the
pharmaceutical,
biotechnology
and
life
sciences
industries.
The
Company
engages
in
chemistry
research,
including
lead
discovery,
optimization,
development
and
commercial
manufacturing.
The
Company
performs
chemistry
research
for
many
leading
pharmaceutical
and
biotechnology
companies
and
for
its
own
internal
research
and
development.
In
addition
to
its
chemistry
research
services,
the
Company
also
conducts
proprietary
research
and
development
to
discover
new
lead
compounds
with
commercial
potential.
The
Company's
analytical
chemistry
services
include
identity
and
purity
testing,
method
development
and
validation,
and
stability
testing. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Albany
Molecular
Research
is
a
drug
discovery
and
development
company
focused
on
applications
for
the
pharmaceutical,
biotechnology
and
life
sciences
industries.
For
the
six
months
ended
6/30/01,
revenues
rose
51%
to
$45.4
million.
Net
income
rose
62%
to
$16.7
million.
Revenues
reflect
increased
medicinal
and
chemical
development
services
contracts
and
the
addition
of
ten
new
customers.
Net
income
also
reflects
improved
contract
rates
and
increased
other
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Thomas D' Ambra, Ph.D., 45 Chairman
and CEO | $3.2M | -- | Donald Kuhla, Ph.D., 58 Pres,
ChiefOperating Officer | 295K | $694K | David Waldek, 36 CFO
and Treasurer | 234K | -- | Lawrence Jones, Ph.D., 49 Sr.
VP, Bus. Devel. | 191K | -- | Michael Trova, Ph.D., 39 Sr.
VP, Medicinal Chemistry | 194K | 705K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|